Vita 34 AG
XETRA:V3V
Vita 34 AG
XETRA:V3V
Price:
4.7 EUR
-1.26%
Market Closed
Updated:
May 9, 2024
EV/S
Enterprise Value to Sales
Enterprise Value to Sales
1
Current
1.6
Median
2.5
Industry
Lower
than median
Lower
than industry value
Enterprise Value to Sales (EV/S) ratio is a valuation multiple that compares the enterprise value (EV) of a company to its revenues. The EV/S multiple gives investors a quantifiable metric of how to value a company based on its sales while taking account of both the company's equity and debt.
EV/S
=1
Enterprise Value
/
75.9m
Revenue
74.9m
All Countries
| Market Cap | EV/S | ||||
|---|---|---|---|---|---|
| DE |
|
Vita 34 AG
XETRA:V3V
|
74.4m EUR | 1 | |
| US |
|
Cigna Corp
NYSE:CI
|
98.7B USD | 0.6 | |
| US |
C
|
Cigna Group
XMUN:CGN
|
91.3B EUR | 0.6 | |
| US |
|
CVS Health Corp
NYSE:CVS
|
68.7B USD | 0.3 | |
| DE |
F
|
Fresenius SE & Co KGaA
XETRA:FRE
|
16B EUR | 1.2 | |
| US |
|
Laboratory Corporation of America Holdings
NYSE:LH
|
17B USD | 1.6 | |
| US |
|
Quest Diagnostics Inc
NYSE:DGX
|
15.1B USD | 2 | |
| DE |
F
|
Fresenius Medical Care AG & Co KGaA
XETRA:FME
|
11.3B EUR | 1.1 | |
| US |
|
DaVita Inc
NYSE:DVA
|
11.9B USD | 1.7 | |
| DE |
|
Fresenius Medical Care AG
XMUN:FME
|
11B EUR | 1 | |
| US |
|
Oak Street Health Inc
NYSE:OSH
|
9.5B USD | 4.6 |
EV/S Forward Multiples
Forward EV/S multiple is a version of the EV/S ratio that uses forecasted revenue for the EV/S calculation. 1-Year, 2-Years, and 3-Years forwards use revenue forecasts for 1, 2, and 3 years ahead, respectively.
1-Year Forward
EV/S
1
2-Years Forward
EV/S
1
3-Years Forward
EV/S
0.9
You don't have any saved screeners yet
